Skip to main content
European Commission logo print header

Integrated Imaging in live Cell Analysis (II-LCA), for enhanced development and manufacturing of biologic and cell therapies.

Project description

Better drug accessibility through innovative cell-based manufacture

Delivering life-saving medication fast and effectively is challenging from an engineering and manufacturing aspect. The II-LCA project changes manufacturing at cell level to make medicine more accessible. The project will fund the recruitment of an innovation associate in the Valitacell company, enhancing its capabilities in cell imaging, life sciences instrumentation and automation, and boosting the creation of new drugs and cellular therapeutics. The reduced cost of and improvement in manufacture will benefit a larger population in Europe, who will also have direct access to new therapies.


The successful recruitment and incorporation of an Innovation associate (IA), with expertise in live cell imaging, life sciences instrumentation and automation, into the Valitacell team is integral to the evolution of our technologies. The IA will dramatically enhance Valitacells capabilities in this space, strengthen existing collaborations, and generate further opportunities for future innovation. If successful, II-LCA will lead to the accelerated development of novel biological drugs and cellular therapeutics, for the treatment of diverse disease indications. European patients will benefit from increased access to targeted and innovative breakthrough therapies, through reduced cost of development and improved manufacturing paradigms.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 123 746,25
Fosters ave. - mount merrion, blackrock
V94 Dublin 2

See on map

Ireland Eastern and Midland Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00